Tagraxofusp and Hepatotoxicity
Result of checking the interaction of drug Tagraxofusp and disease Hepatotoxicity for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Treatment with tagraxofusp was associated with elevations in liver enzymes in patients in clinical trials. Elevations in liver enzymes occurred in 88% of patients. Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with tagraxofusp. Withhold treatment temporarily if the transaminases rise to greater than 5 times the upper limit of normal and resume treatment upon normalization or when resolved. Additionally, severe hepatic impairment (total bilirubin >3 times ULN and any AST) on tagraxofusp pharmacokinetics is unknown. No clinically significant differences in the pharmacokinetics were observed in patients with mild or moderate hepatic impairment.
Tagraxofusp - hepatotoksyczność 
Tagraxofusp - hepatotoxicidade 
Tagraxofusp - hepatotoksisiti 
Tagraxofusp - hepatotoksisitas 
Tagraxofusp - epatotossicità 
Tagraxofusp - hépatotoxicité 
Tagraxofusp - Hepatotoxizität 
Tagraxofusp - hepatotoxicidad 
Tagraxofusp - гепатотоксичность 
Tagraxofusp - hepatotoksisite 
Tagraxofusp - السمية الكبدية 
Tagraxofusp - 肝毒性